Table Info

Table 2.

Adverse events when using benzbromarone in 98 patients

Adverse events using benzbromarone	Low excretors (n = 36)	Normal to high excretors (n = 27)	Unknown excretor type at baseline (n = 35)	Total (n = 98)
Medical decision to stop benzbromarone	10 (28%)	4 (15%)	4 (11%)	18 (18%)
Renal stones	0	0	1 (3%)	1 (1%)
Decreased renal function	0	2 (7%)	2 (6%)	4 (4%)
Diarrhea	4 (11%)	3 (11%)	2 (6%)	9 (9%)
Patient decision to stop benzbromarone (subjective reasons)	0	5 (18%)	1 (3%)	6 (6%)
Liver toxicity	0	1 (4%)	0	1 (1%)
Ongoing therapy	13 (36%)	7 (26%)	18 (51%)	38 (38%)

The data in the table is presented in the form of “n (percentage)”

Supplementary materials

The supplementary material for this article is available at: https://www.explorationpub.com/uploads/Article/file/100719_sup_1.pdf.

Declarations

Author contributions

IH: Data curation, Formal analysis, Investigation, Methodology, Visualization, Writing—original draft, Writing—review & editing. MJ: Methodology, Resources, Validation, Writing—review & editing. TLJ: Conceptualization, Investigation, Methodology, Project administration, Resources, Supervision, Validation, Writing—review & editing. All authors read and approved the submitted version.

Conflict of interest

The authors declare that they have no conflicts of interest.

Ethical approval

The institutional review board of VieCuri Medical Center (2021-009), Venlo, Netherlands approved the study.

Consent to participate

Due to the retrospective and observational approach of the study a waiver of informed consent was provided.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

IH was supported by European League Against Rheumatism (EULAR). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

References

Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castañeda-Sanabria J, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2016;76:29–42. [DOI] [PubMed]

Siddiq MAB, Jansen TL, Rasker JJ. What is the place for uricosuric agents in gout management? Curr Rheumatol Rev. 2022;18:279–85. [DOI] [PubMed]

Jansen TL, Tanja G, Matthijs J. A historical journey of searching for uricosuric drugs. Clin Rheumatol. 2022;41:297–305. [DOI] [PubMed]

Hosoya T, Fushimi M, Okui D, Sasaki T, Ohashi T. Open-label study of long-term administration of dotinurad in Japanese hyperuricemic patients with or without gout. Clin Exp Nephrol. 2020;24:80–91. [DOI] [PubMed] [PMC]

Miner JN, Tan PK, Hyndman D, Liu S, Iverson C, Nanavati P, et al. Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney. Arthritis Res Ther. 2016;18:214. Erratum in: Arthritis Res Ther. 2016;18:236. [DOI] [PubMed] [PMC]

Pérez-Ruiz F, Jansen T, Tausche AK, Juárez-Campo M, Gurunath RK, Richette P. Efficacy and safety of lesinurad for the treatment of hyperuricemia in gout. Drugs Context. 2019;8:212581. [DOI] [PubMed] [PMC]

Fitz-Patrick D, Roberson K, Niwa K, Fujimura T, Mori K, Hall J, et al. Safety and efficacy of verinurad, a selective URAT1 inhibitor, for the treatment of patients with gout and/or asymptomatic hyperuricemia in the United States and Japan: findings from two phase II trials. Mod Rheumatol. 2019;29:1042–52. [DOI] [PubMed]

Ishikawa T, Takahashi T, Taniguchi T, Hosoya T. Dotinurad: a novel selective urate reabsorption inhibitor for the treatment of hyperuricemia and gout. Expert Opin Pharmacother. 2021;22:1397–406. [DOI] [PubMed]

Gutman AB. Uricosuric drugs, with special reference to probenecid and sulfinpyrazone. Adv Pharmacol. 1966;4:91–142. [DOI] [PubMed]

10.

Cunningham RF, Israili ZH, Dayton PG. Clinical pharmacokinetics of probenecid. Clin Pharmacokinet. 1981;6:135–51. [DOI] [PubMed]

11.

Stocker SL, Graham GG, McLachlan AJ, Williams KM, Day RO. Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout. J Rheumatol. 2011;38:904–10. [DOI] [PubMed]

12.

Jansen TL, Reinders MK, van Roon EN, Brouwers JR. Benzbromarone withdrawn from the European market: another case of “absence of evidence is evidence of absence”? Clin Exp Rheumatol. 2004;22:651. [PubMed]

13.

Reinders MK, van Roon EN, Houtman PM, Brouwers JR, Jansen TL. Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients. Clin Rheumatol. 2007;26:1459–65. [DOI] [PubMed]

14.

Reinders MK, van Roon EN, Jansen TL, Delsing J, Griep EN, Hoekstra M, et al. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. Ann Rheum Dis. 2009;68:51–6. [DOI]

15.

Azevedo VF, Kos IA, Vargas-Santos AB, da Rocha Castelar Pinheiro G, Dos Santos Paiva E. Benzbromarone in the treatment of gout. Adv Rheumatol. 2019;59:37. [DOI] [PubMed]

16.

Reinders MK, Haagsma C, Jansen TL, van Roon EN, Delsing J, van de Laar MA, et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300–600 mg/day versus benzbromarone 100–200 mg/day in patients with gout. Ann Rheum Dis. 2009;68:892–7. [DOI] [PubMed]

17.

Liang N, Sun M, Sun R, Xu T, Cui L, Wang C, et al. Baseline urate level and renal function predict outcomes of urate-lowering therapy using low doses of febuxostat and benzbromarone: a prospective, randomized controlled study in a Chinese primary gout cohort. Arthritis Res Ther. 2019;21:200. [DOI] [PubMed] [PMC]

18.

Yu H, Liu X, Song Y, Cheng J, Bao H, Qin L, et al. Safety and efficacy of benzbromarone and febuxostat in hyperuricemia patients with chronic kidney disease: a prospective pilot study. Clin Exp Nephrol. 2018;22:1324–30. [DOI] [PubMed]

19.

Stamp LK, Haslett J, Frampton C, White D, Gardner D, Stebbings S, et al. The safety and efficacy of benzbromarone in gout in Aotearoa New Zealand. Intern Med J. 2016;46:1075–80. [DOI]

20.

Hosoya T, Furuno K, Kanda S. A clinical pharmacology study of the novel, selective urate reabsorption inhibitor dotinurad in outpatients. Clin Exp Nephrol. 2020;24:103–11. [DOI] [PubMed] [PMC]

21.

Tausche AK, Alten R, Dalbeth N, Kopicko J, Fung M, Adler S, et al. Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6 month phase 3 clinical trial and extension study. Rheumatology (Oxford). 2017;56:2170–8. [DOI]

22.

Dalbeth N, Jones G, Terkeltaub R, Khanna D, Kopicko J, Bhakta N, et al. Lesinurad, a selective uric acid reabsorption inhibitor, in combination with febuxostat in patients with tophaceous gout: findings of a phase III clinical trial. Arthritis Rheumatol. 2017;69:1903–13. [DOI] [PubMed] [PMC]

23.

Bardin T, Keenan RT, Khanna PP, Kopicko J, Fung M, Bhakta N, et al. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). Ann Rheum Dis. 2017;76:811–20. [DOI] [PubMed] [PMC]

24.

Xue X, Yuan X, Han L, Li X, Merriman TR, Cui L, et al. Effect of clinical typing on serum urate targets of benzbromarone in chinese gout patients: a prospective cohort study. Front Med (Lausanne). 2022;8:806710. [DOI] [PubMed] [PMC]